{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:36Z","timestamp":1786119456758,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1097\/mph.0b013e3181d74702","type":"journal-article","created":{"date-parts":[[2010,5,12]],"date-time":"2010-05-12T03:56:27Z","timestamp":1273636587000},"page":"511-514","source":"Crossref","is-referenced-by-count":13,"title":["Sorafenib Plus Valproic Acid for Infant Spinal Glioblastoma"],"prefix":"10.1097","volume":"32","author":[{"given":"Christopher Alan","family":"Rokes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Remke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Guha-Thakurta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Korshunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes E.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210227","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11060-007-9507-z","article-title":"Descriptive epidemiology of primary spinal cord tumors","volume":"87","author":"Schellinger","year":"2008","journal-title":"J Neuro-Oncol"},{"key":"R2-16-20210227","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3171\/jns.1989.70.1.0050","article-title":"Malignant astrocytomas of the spinal cord","volume":"70","author":"Cohen","year":"1989","journal-title":"J Neurosurg"},{"key":"R3-16-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000028751","article-title":"High-grade pediatric spinal cord tumors","volume":"30","author":"Merchant","year":"1999","journal-title":"Pediatr Neurosurg"},{"key":"R4-16-20210227","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF02001471","article-title":"Management of intramedullary tumours in children","volume":"120","author":"Lunardi","year":"1993","journal-title":"Acta Neurochir (Wien)"},{"key":"R5-16-20210227","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3171\/jns.1996.85.6.1036","article-title":"Intramedullary spinal cord tumors in children under the age of 3 years","volume":"85","author":"Constantini","year":"1996","journal-title":"J Neurosurg"},{"key":"R6-16-20210227","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3171\/jns.1998.88.2.0215","article-title":"Treatment of high-grade spinal cord astrocytoma of childhood with \u201c8-in-1\u201d chemotherapy and radiotherapy: a pilot study of CCG-945. Children's Cancer Group","volume":"88","author":"Allen","year":"1998","journal-title":"J Neurosurg"},{"key":"R7-16-20210227","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11060-007-9495-z","article-title":"Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database","volume":"87","author":"Wolff","year":"2008","journal-title":"J Neuro-Oncol"},{"key":"R8-16-20210227","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/pbc.20083","article-title":"Valproic acid treatment of glioblastoma multiforme in a child","volume":"43","author":"Witt","year":"2004","journal-title":"Pediatric Blood Cancer"},{"key":"R9-16-20210227","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11060-008-9662-x","article-title":"Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma","volume":"90","author":"Wolff","year":"2008","journal-title":"J Neuro-Oncol"},{"key":"R10-16-20210227","first-page":"2437","article-title":"Influence of valproic acid on outcome of high-grade gliomas in children","volume":"28","author":"Masoudi","year":"2008","journal-title":"Anticancer Res"},{"key":"R11-16-20210227","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1215\/15228517-2006-036","article-title":"Molecular pathogenesis of pediatric astrocytic tumors","volume":"9","author":"Nakamura","year":"2007","journal-title":"Neuro-Oncology"},{"key":"R12-16-20210227","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"key":"R13-16-20210227","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/WCO.0b013e3282f15650","article-title":"New molecular targets in malignant gliomas","volume":"20","author":"de Groot","year":"2007","journal-title":"Current Opinion Neurol"},{"key":"R14-16-20210227","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.2006.07.8626","article-title":"Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors","volume":"25","author":"Faury","year":"2007","journal-title":"J Clin Oncol"},{"key":"R15-16-20210227","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1172\/JCI33656","article-title":"BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas","volume":"118","author":"Pfister","year":"2008","journal-title":"J Clin Invest"},{"key":"R16-16-20210227","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R17-16-20210227","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/jpet.106.108621","article-title":"Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells","volume":"319","author":"Jane","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"R18-16-20210227","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R19-16-20210227","first-page":"3585","article-title":"Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro","volume":"18","author":"Knupfer","year":"1998","journal-title":"Anticancer Res"},{"key":"R20-16-20210227","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","article-title":"Valproic acid induces p21 and topoisomerase-II (alpha\/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines","volume":"85","author":"Das","year":"2007","journal-title":"J Neuro-Oncol"},{"key":"R21-16-20210227","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1158\/1078-0432.CCR-08-0469","article-title":"Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation","volume":"14","author":"Zhang","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R22-16-20210227","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.3748\/wjg.v13.i33.4458","article-title":"Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells","volume":"13","author":"Baradari","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R23-16-20210227","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1124\/mol.109.056309","article-title":"BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing","volume":"76","author":"Martin","year":"2009","journal-title":"Mol Pharmacol"},{"key":"R24-16-20210227","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6004\/jnccn.2008.0039","article-title":"Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities","volume":"6","author":"Wong","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"R25-16-20210227","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3171\/2008.7.JNS08143","article-title":"Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma","volume":"111","author":"Hill","year":"2009","journal-title":"J Neurosurg"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0b013e3181d74702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:20:50Z","timestamp":1786040450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00043426-201008000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e3181d74702","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}